CHMP Thumbs Up For Bayer's Hemophilia A Product
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Bayer's Kovaltry (octocog alfa) and Iblias (octocog alfa). The products, which have also been referred to as BAY 81-8973 by the company, are intended for the treatment of bleeding in patients of all ages with congenital factor VIII deficiency, hemophilia A.